exhibit 10. 5 certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the commission. confidential portions are marked [ * * ]. license agreement by and between orthocyte corporation a california corporation and an affiliate of biotime, inc. ( “ biotime ” ), 1301 harbor bay parkway, alameda, ca 94502 usa ( in the following referred to as “ orthocyte ” ) and heraeus medical gmbh philip - reis - str. 8 / 13 61273 wehrheim, germany ( in the following referred to as “ heraeus ” ) by and between by and between orthocyte corporation orthocyte corporation a california corporation and an affiliate a california corporation and an affiliate of biotime, inc. ( “ biotime ” ), of biotime, inc. ( “ biotime ” ), 1301 harbor bay parkway, 1301 harbor bay parkway, alameda, ca 94502 usa alameda, ca 94502 usa ( in the following referred to as “ orthocyte ” ) ( in the following referred to as “ orthocyte ” ) and and heraeus medical gmbh heraeus medical gmbh philip - reis - str. 8 / 13 philip - reis - str. 8 / 13 61273 wehrheim, germany 61273 wehrheim, germany ( in the following referred to as “ heraeus ” ) ( in the following referred to as “ heraeus ” ) orthocyte and heraeus may in the following be referred to individually as a “ party ” and collectively as the “ parties ”. preamble whereas orthocyte owns, or has licensed rights to, and possesses two therapeutic development platforms. the first one being a comprehensive portfolio of embryonic stem cells and clonal progenitor stem cells of primate origin, as well as related know - how and technological expertise to propagate and differentiate these cells. more specifically, the first platform comprises osteochondro progenitor cell lines named purestem® and related know - how and technological expertise to ensure the isolation and selection of clonal cells with high purity and optimised potency, including methods to ensure scalability of culturing and identification by comprehensive microarrays. the second platform technology is a scaffold technology for cell delivery, named hystem